{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:22:04Z","timestamp":1790457724412,"version":"4.1.0"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,11]]},"DOI":"10.18632\/oncotarget.13286","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T16:43:38Z","timestamp":1478882618000},"page":"24303-24313","source":"Crossref","is-referenced-by-count":47,"title":["ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer"],"prefix":"10.18632","volume":"8","author":[{"given":"Issam","family":"Chebouti","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Dominik","family":"Kuhlmann","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Buderath","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weber","sequence":"additional","affiliation":[{"name":"ACOMED Statistik, Department of Biostatics, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Bokeloh","sequence":"additional","affiliation":[{"name":"QIAGEN Hannover GmbH, Langenhagen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Hauch","sequence":"additional","affiliation":[{"name":"QIAGEN Hannover GmbH, Langenhagen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Kimmig","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kasimir-Bauer","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1002\/cncr.11349","article-title":"Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997","volume":"97","author":"Chen","year":"2003","journal-title":"Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"Fujiwara","year":"2005","journal-title":"Ann Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO)","volume":"115","author":"Pfisterer","year":"2009","journal-title":"Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2007.02.026","article-title":"Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study G. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)","volume":"106","author":"Du Bois","year":"2007","journal-title":"Gynecol Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1245\/s10434-010-0964-9","article-title":"Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)","volume":"17","author":"du Bois","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.seminoncol.2008.12.003","article-title":"Management of recurrent ovarian carcinoma: current status and future directions","volume":"36","author":"Schilder","year":"2009","journal-title":"Semin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"key":"8","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Kroemer","year":"2012","journal-title":"Oncogene"},{"key":"9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/1097-0215(20000920)89:5<453::AID-IJC9>3.0.CO;2-E","article-title":"ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells","volume":"89","author":"Murray","year":"2000","journal-title":"Int J Cancer"},{"key":"10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/tpj.2011.29","article-title":"TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials","volume":"12","author":"Lenz","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3892\/ol.2012.1096","article-title":"The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy","volume":"5","author":"Pan","year":"2013","journal-title":"Oncol Lett"},{"key":"12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Pignon","year":"2006","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.dnarep.2010.03.010","article-title":"Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells","volume":"9","author":"Patrick","year":"2010","journal-title":"DNA Repair (Amst)"},{"key":"14","first-page":"708","article-title":"Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy","volume":"16","author":"Gavrilovic","year":"2011","journal-title":"J BUON"},{"key":"15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2010.07.018","article-title":"Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma","volume":"119","author":"Fisseler-Eckhoff","year":"2010","journal-title":"Gynecol Oncol"},{"key":"16","first-page":"86","article-title":"[The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance] [Article in Chinese]","volume":"42","author":"Yang","year":"2011","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/IGC.0b013e318218f28b","article-title":"Expression of ERCC1, p53, and class III beta-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study","volume":"21","author":"Amant","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00428-011-1110-1","article-title":"Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy","volume":"459","author":"Fend","year":"2011","journal-title":"Virchows Arch"},{"key":"19","doi-asserted-by":"crossref","first-page":"e25164","DOI":"10.1371\/journal.pone.0025164","article-title":"Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations","volume":"6","author":"Popat","year":"2011","journal-title":"PLoS One"},{"key":"20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Solary","year":"2013","journal-title":"New Engl J Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","article-title":"ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance","volume":"60","author":"Kasimir-Bauer","year":"2014","journal-title":"Clin Chem"},{"key":"22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1471-2164-9-246","article-title":"Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate","volume":"9","author":"Liu","year":"2008","journal-title":"BMC Genomics"},{"key":"23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/gb-2003-4-9-117","article-title":"Comparing protein abundance and mRNA expression levels on a genomic scale","volume":"4","author":"Gerstein","year":"2003","journal-title":"Genome Biol"},{"key":"24","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1534\/genetics.106.065862","article-title":"Correlation of mRNA expression and protein abundance affected by multiple sequence features related to translational efficiency in Desulfovibrio vulgaris: a quantitative analysis","volume":"174","author":"Zhang","year":"2006","journal-title":"Genetics"},{"key":"25","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.molonc.2016.04.002","article-title":"Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel","volume":"10","author":"Neubauer","year":"2016","journal-title":"Mol Oncol"},{"issue":"7","key":"26","doi-asserted-by":"publisher","first-page":"26107","DOI":"10.18632\/oncotarget.8431","article-title":"Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer","volume":"3","author":"Pinzani","year":"2016","journal-title":"Oncotarget"},{"key":"27","doi-asserted-by":"publisher","first-page":"48625","DOI":"10.18632\/oncotarget.8015","article-title":"Evaluation and consequences of heterogeneity in the circulating tumor cell compartment","volume":"7","author":"Van Laere","year":"2016","journal-title":"Oncotarget"},{"key":"28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13058-016-0679-3","article-title":"Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy","volume":"18","author":"Hoffmann","year":"2016","journal-title":"Breast Cancer Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/IGC.0b013e318216cb91","article-title":"Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy","volume":"21","author":"Wimberger","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/bjc.2013.419","article-title":"Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment","volume":"109","author":"Hoffmann","year":"2013","journal-title":"Br J Cancer"},{"key":"31","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nbt.2576","article-title":"Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay","volume":"31","author":"Sprick","year":"2013","journal-title":"Nat Biotechnol"},{"key":"32","doi-asserted-by":"publisher","first-page":"26454","DOI":"10.18632\/oncotarget.8524","article-title":"Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?","volume":"7","author":"Kasimir-Bauer","year":"2016","journal-title":"Oncotarget"},{"key":"33","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1158\/1535-7163.MCT-12-1028","article-title":"Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924","volume":"12","author":"Dutta","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"34","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbrc.2010.03.029","article-title":"Role of the Akt\/mTOR survival pathway in cisplatin resistance in ovarian cancer cells","volume":"394","author":"Wu","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/1471-2407-14-562","article-title":"3\u2019-ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction","volume":"14","author":"Oie","year":"2014","journal-title":"BMC Cancer"},{"key":"36","doi-asserted-by":"publisher","first-page":"41677","DOI":"10.18632\/oncotarget.9528","article-title":"Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment","volume":"7","author":"Kasimir-Bauer","year":"2016","journal-title":"Oncotarget"},{"key":"37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathologic grading of ovarian carcinoma: a review and proposal","volume":"19","author":"Silverberg","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009; 105:3\u20134.","DOI":"10.1016\/j.ijgo.2008.12.015"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T18:04:27Z","timestamp":1589133867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":38,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,4,11]]}},"alternative-id":["13286","28388557"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13286","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]}}}